108 related articles for article (PubMed ID: 12972998)
21. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071
[TBL] [Abstract][Full Text] [Related]
22. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer.
Yang SN; Liang JA; Lin FJ; Kao CH; Lin CC; Lee CC
J Cancer Res Clin Oncol; 2002 Jun; 128(6):325-8. PubMed ID: 12073051
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG-PET/CT in implant-associated anaplastic large cell lymphoma of the breast.
Acevedo-Báñez I; García-Gomez FJ; Jiménez-Granero P; Carrillo-Cruz E; Perez-Lopez O; Borrego-Dorado I
Br J Haematol; 2015 Apr; 169(1):1. PubMed ID: 25521839
[No Abstract] [Full Text] [Related]
24. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography.
Pecking AP; Mechelany-Corone C; Bertrand-Kermorgant F; Alberini JL; Floiras JL; Goupil A; Pichon MF
Clin Breast Cancer; 2001 Oct; 2(3):229-34. PubMed ID: 11899417
[TBL] [Abstract][Full Text] [Related]
25. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
26. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
[TBL] [Abstract][Full Text] [Related]
27. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
[TBL] [Abstract][Full Text] [Related]
28. Abnormal FDG uptake on 18F-fluorodeoxyglucose positron emission tomography in patients with cancer diagnosis: case reports of tuberculous lymphadenitis.
Ataergin S; Arslan N; Ozet A; Ozguven MA
Intern Med; 2009; 48(2):115-9. PubMed ID: 19145057
[TBL] [Abstract][Full Text] [Related]
29. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
30. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
31. Case 256: Breast Implant-associated Anaplastic Large-Cell Lymphoma.
Eisenberg AM; Eppelheimer CN; Fulop TA; Abramson LL
Radiology; 2018 Aug; 288(2):624-629. PubMed ID: 30020870
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
Sakurai H; Suzuki Y; Nonaka T; Ishikawa H; Shioya M; Kiyohara H; Katoh H; Nakayama Y; Hasegawa M; Nakano T
Gynecol Oncol; 2006 Mar; 100(3):601-7. PubMed ID: 16257440
[TBL] [Abstract][Full Text] [Related]
33. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
34. Disseminated tuberculosis masquerading as metastatic breast carcinoma on PET-CT.
Das CJ; Kumar R; Balakrishnan VB; Chawla M; Malhotra A
Clin Nucl Med; 2008 May; 33(5):359-61. PubMed ID: 18431158
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
36. The role of positron emission tomographic imaging in breast cancer.
McDonough MD; DePeri ER; Mincey BA
Curr Oncol Rep; 2004 Jan; 6(1):62-8. PubMed ID: 14664763
[TBL] [Abstract][Full Text] [Related]
37. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
Yun M; Choi HS; Yoo E; Bong JK; Ryu YH; Lee JD
J Nucl Med; 2005 Jun; 46(6):953-7. PubMed ID: 15937305
[TBL] [Abstract][Full Text] [Related]
38. Preoperative FDG-PET for axillary metastases in patients with breast cancer.
Chung A; Liou D; Karlan S; Waxman A; Fujimoto K; Hagiike M; Phillips EH
Arch Surg; 2006 Aug; 141(8):783-8; discussion 788-9. PubMed ID: 16924086
[TBL] [Abstract][Full Text] [Related]
39. [Positron emission tomography (PET) in diagnosis of breast carcinoma].
Ivancevic V
Zentralbl Chir; 1998; 123 Suppl 5():53-6. PubMed ID: 10063574
[TBL] [Abstract][Full Text] [Related]
40. The role of FDG-PET/CT in suspected recurrence of breast cancer.
Radan L; Ben-Haim S; Bar-Shalom R; Guralnik L; Israel O
Cancer; 2006 Dec; 107(11):2545-51. PubMed ID: 17063499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
